Aneurysmal subarachnoid haemorrhage: effect of CRHR1 genotype on fatigue and depression.
Aneurysm
CRHR1
Cortitrophin-releasing hormone receptor-type 1
Depression
Fatigue
Gene
Mental health
SNP
Subarachnoid haemorrhage
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
18 Apr 2020
18 Apr 2020
Historique:
received:
31
07
2019
accepted:
14
04
2020
entrez:
20
4
2020
pubmed:
20
4
2020
medline:
12
9
2020
Statut:
epublish
Résumé
Emotional health disturbances are common after aneurysmal subarachnoid hemorrhage (aSAH) and their causes are largely unexplored. Corticotropin-releasing hormone receptor 1 (CRHR1) is a key factor in stress reactivity and development of mental health disturbances after adverse life-events. We explore the effect of CRHR1 genotype on mental health after aSAH in a retrospective cohort study. One hundred twenty-five patients have been assessed using EST-Q mental health questionnaire. Genotyping of CRHR1 single nucleotide polymorphisms (SNP-s) was performed (Rs7209436, Rs110402, Rs242924). Fatigue was present in almost half of aSAH patients, depression and anxiety in one-third. There was a high prevalence of insomnia and panic complaints. Rs110402 minor allele decreased the risk of depression (OR = 0.25, p = 0.027 for homozygotes). Depression was present in 14% vs 41% in minor and major allele homozygotes, respectively. Rs110402, Rs242924 and Rs7209436 minor alleles and TAT-haplotype, formed by them, were protective against fatigue. After Bonferroni correction only the association of Rs110402 with fatigue remained statistically significant (OR = 0.21, p = 0.006 for minor allele homozygotes). Results remained statistically significant when adjusted for gender, admission state, age and time from aSAH. In multiple regression analysis occurrence of fatigue was dependent on anxiety, modified Rankin score and Rs110402 genotype (R CRHR1 minor genotype was associated with a lower risk of fatigue and depression after aSAH. Genetic predisposition to mental health disturbances associated with negative life-events could be a risk factor for fatigue and depression after aSAH and selected patients might benefit from advanced counselling in the recovery phase.
Sections du résumé
BACKGROUND
BACKGROUND
Emotional health disturbances are common after aneurysmal subarachnoid hemorrhage (aSAH) and their causes are largely unexplored. Corticotropin-releasing hormone receptor 1 (CRHR1) is a key factor in stress reactivity and development of mental health disturbances after adverse life-events.
METHODS
METHODS
We explore the effect of CRHR1 genotype on mental health after aSAH in a retrospective cohort study. One hundred twenty-five patients have been assessed using EST-Q mental health questionnaire. Genotyping of CRHR1 single nucleotide polymorphisms (SNP-s) was performed (Rs7209436, Rs110402, Rs242924).
RESULTS
RESULTS
Fatigue was present in almost half of aSAH patients, depression and anxiety in one-third. There was a high prevalence of insomnia and panic complaints. Rs110402 minor allele decreased the risk of depression (OR = 0.25, p = 0.027 for homozygotes). Depression was present in 14% vs 41% in minor and major allele homozygotes, respectively. Rs110402, Rs242924 and Rs7209436 minor alleles and TAT-haplotype, formed by them, were protective against fatigue. After Bonferroni correction only the association of Rs110402 with fatigue remained statistically significant (OR = 0.21, p = 0.006 for minor allele homozygotes). Results remained statistically significant when adjusted for gender, admission state, age and time from aSAH. In multiple regression analysis occurrence of fatigue was dependent on anxiety, modified Rankin score and Rs110402 genotype (R
CONCLUSIONS
CONCLUSIONS
CRHR1 minor genotype was associated with a lower risk of fatigue and depression after aSAH. Genetic predisposition to mental health disturbances associated with negative life-events could be a risk factor for fatigue and depression after aSAH and selected patients might benefit from advanced counselling in the recovery phase.
Identifiants
pubmed: 32305063
doi: 10.1186/s12883-020-01727-y
pii: 10.1186/s12883-020-01727-y
pmc: PMC7165373
doi:
Substances chimiques
Receptors, Corticotropin-Releasing Hormone
0
CRF receptor type 1
5CLY6W2H1M
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
142Subventions
Organisme : Eesti Teadusagentuur
ID : IUT20-46
Organisme : Eesti Teadusagentuur
ID : IUT20-46
Organisme : Eesti Teadusagentuur
ID : IUT2-4
Références
J Crit Care. 2014 Feb;29(1):101-6
pubmed: 24075295
Neuropsychopharmacology. 2017 Nov;42(12):2446-2455
pubmed: 28589964
Br J Neurosurg. 2011 Dec;25(6):693-700
pubmed: 21591856
Eur Psychiatry. 2010 Jun;25(5):278-80
pubmed: 20444578
Endocr Connect. 2018 Jun;7(6):R223-R237
pubmed: 29748174
Psychoneuroendocrinology. 2011 Jun;36(5):720-7
pubmed: 21093988
Neurology. 2018 Dec 4;91(23):e2182-e2191
pubmed: 30381370
Psychoneuroendocrinology. 2019 Apr;102:44-52
pubmed: 30513499
Ann N Y Acad Sci. 2006 Jul;1071:46-53
pubmed: 16891561
Lancet Neurol. 2009 Jul;8(7):635-42
pubmed: 19501022
J Stroke Cerebrovasc Dis. 2015 Mar;24(3):618-21
pubmed: 25542762
Int J Stroke. 2016 Dec;11(9):968-977
pubmed: 27703065
Psychoneuroendocrinology. 2019 Feb;100:156-163
pubmed: 30340064
Fam Pract. 2006 Dec;23(6):693-8
pubmed: 17035287
J Neurosurg. 2014 Apr;120(4):923-30
pubmed: 24359009
Sci Rep. 2020 Jan 20;10(1):724
pubmed: 31959877
J Stroke Cerebrovasc Dis. 2013 Oct;22(7):e189-96
pubmed: 23253535
Neurology. 2013 Jan 22;80(4):409-16
pubmed: 23339207
J Neuropsychiatry Clin Neurosci. 2017 Winter;29(1):67-69
pubmed: 27417068
Stroke Res Treat. 2015;2015:347920
pubmed: 26101691
Neurosurgery. 2010 Apr;66(4):772-83
pubmed: 20190663
Neurology. 2002 Dec 10;59(11):1750-8
pubmed: 12473764
Lancet Neurol. 2011 Apr;10(4):349-56
pubmed: 21435599
J Neurosurg. 1968 Jan;28(1):14-20
pubmed: 5635959
JAMA Neurol. 2019 May 1;76(5):588-597
pubmed: 30659573
Acta Neurochir (Wien). 2013 Jun;155(6):1107-14
pubmed: 23532345
Cost Eff Resour Alloc. 2010 Apr 27;8:6
pubmed: 20423472
J Clin Psychiatry. 1999 Apr;60(4):221-5
pubmed: 10221281
Psychoneuroendocrinology. 2014 May;43:71-80
pubmed: 24703172
Psychoneuroendocrinology. 2009 Sep;34(8):1235-41
pubmed: 19386421
Psychiatr Danub. 2010 Jun;22(2):198-202
pubmed: 20562747
Arch Phys Med Rehabil. 2003 Nov;84(11):1714-20
pubmed: 14639575
Handb Clin Neurol. 2014;124:69-91
pubmed: 25248580
Stroke. 1988 May;19(5):604-7
pubmed: 3363593
Neurosci Lett. 2007 Mar 6;414(2):155-8
pubmed: 17258395
Stroke. 2017 Feb;48(2):e30-e43
pubmed: 27932603
Sci Rep. 2013;3:1548
pubmed: 23529111
Stroke Res Treat. 2017;2017:2124743
pubmed: 28321357